What is the Origin of PT-141 Efficacy Metrics?

PT-141 was developed based on the discovery of the melanocortin system's role in central nervous system-mediated sexual arousal, with clinical trials beginning in the early 2000s. The efficacy metrics were established during the drug's development to provide objective, standardized measures of a subjective clinical endpoint—sexual function.

What is the Mechanism of PT-141 Efficacy Metrics?

The peptide's efficacy is mechanistically linked to its action as a non-selective agonist of melanocortin receptors (MC1R and MC4R) in the central nervous system, which modulates neural pathways involved in sexual motivation and arousal. The metrics quantify the downstream clinical effect of this central neuromodulation, translating the molecular action into a measurable improvement in the patient's sexual health and quality of life.

PT-141 Efficacy Metrics ∞ Area

PT-141 Efficacy Metrics

Meaning

The quantifiable measures used in clinical practice to determine the therapeutic success and functional outcome of treatment with PT-141 (Bremelanotide), a synthetic peptide analog used to treat hypoactive sexual desire disorder (HSDD) in women and erectile dysfunction in men. Efficacy metrics include validated patient-reported outcome measures (PROMs) such as the Female Sexual Function Index (FSFI) or the International Index of Erectile Function (IIEF). The assessment must also include tracking the frequency and intensity of desired sexual response and any potential side effects.